Screening people with type 1 diabetes for albuminuria at intervals determined by their baseline albumin excretion rate and glycated hemoglobin level reduces the time spent with undetected kidney disease, show DCCT/EDIC data.
A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.